<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055770</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01432</org_study_id>
    <secondary_id>NCI-2012-01432</secondary_id>
    <secondary_id>OSU-0213</secondary_id>
    <secondary_id>NCI-5393</secondary_id>
    <secondary_id>CDR0000271197</secondary_id>
    <secondary_id>OSU-02H0084</secondary_id>
    <secondary_id>OSU 0213</secondary_id>
    <secondary_id>5393</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00055770</nct_id>
  </id_info>
  <brief_title>Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer</brief_title>
  <official_title>A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating
      patients who have locally advanced, recurrent, or metastatic head and neck cancer. Erlotinib
      may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs
      used in chemotherapy work in different ways to stop tumor cells from dividing so they stop
      growing or die. Combining erlotinib with docetaxel may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the maximum tolerated dose and dose-limiting toxicity of erlotinib when
      administered in combination with docetaxel in patients with locally advanced, metastatic, or
      recurrent squamous cell carcinoma of the head and neck.

      II. Determine the response rate, duration of response, time to progression, and survival of
      patients treated with this regimen.

      III. Determine the pharmacokinetics of this regimen in these patients. IV. Correlate the
      presence of PTEN, RB, P-Akt, p15, p16, cyclin D1, p27, and p53 genes in tumor tissue with
      response in patients treated with this regimen.

      OUTLINE: This is a phase I, dose-escalation study of erlotinib followed by a phase II study.

      PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour
      on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the
      absence of disease progression or unacceptable toxicity.

      Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is
      determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience
      dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients
      receives erlotinib at the MTD.

      PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of erlotinib and docetaxel, based on incidence of DLT graded according to NCI CTC version 2.0 (Phase I)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with an objective response (Phase II)</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate as measured by RECIST criteria (Phase II)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (Phase II)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival (Phase II)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Stage III Salivary Gland Cancer</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Salivary Gland Cancer</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.
Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.
PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and neck
             meeting 1 of the following staging criteria:

               -  Recurrent

               -  Metastatic

               -  Locally advanced and determined to be incurable by surgery or radiotherapy

          -  Measurable disease

          -  No known brain metastases

          -  Performance status - ECOG 0-2

          -  Performance status - Karnofsky 60-100%

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin normal

          -  AST and ALT no greater than 2.5 times upper limit of normal

          -  Creatinine normal

          -  Creatinine clearance at least 60 mL/min

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No severe pulmonary insufficiency, including chronic obstructive pulmonary disease,
             requiring oxygen (O2 saturation less than 90%) and/or increase in PaCO2 blood gas
             level greater than 50 mm Hg

          -  No history of abnormality of the cornea (e.g., dry eye syndrome or Sj√∂gren's syndrome)

          -  No congenital abnormality (e.g., Fuch's dystrophy)

          -  No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)

          -  No abnormal corneal sensitivity test (Schirmer test or similar tear production test)

          -  Able to take oral medication

          -  No requirement for IV alimentation

          -  No active peptic ulcer disease

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No significant traumatic injury within the past 21 days

          -  No prior allergic reactions to compounds of similar chemical or biological composition
             to study drugs

          -  No grade 2 or greater persistent peripheral neuropathy

          -  No other concurrent uncontrolled illness that would preclude study participation

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No prior immunotherapy for head and neck cancer

          -  No more than 1 prior chemotherapy regimen in the adjuvant or neoadjuvant setting

          -  No more than 1 prior chemotherapy regimen for metastatic disease

          -  No prior docetaxel (phase II only)

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and
             recovered

          -  No prior hormonal therapy for head and neck cancer

          -  Prior external beam radiotherapy allowed

          -  At least 4 weeks since prior radiotherapy and recovered

          -  More than 21 days since prior major surgery

          -  No prior surgery affecting gastrointestinal absorption

          -  No prior epidermal growth factor receptor-targeting therapy

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapies or agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Kraut</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

